Search Results - "Jardin, F."

Prognostic value of the combination of volume, massiveness and fragmentation parameters measured on baseline FDG pet in high-burden follicular lymphoma by Draye-Carbonnier, S., Camus, V., Becker, S., Tonnelet, D., Lévêque, E., Zduniak, A., Jardin, F., Tilly, H., Vera, P., Decazes, P.

“…The prognostic value of radiomic quantitative features measured on pre-treatment 18 F-FDG PET/CT was investigated in patients with follicular lymphoma (FL). We…”
Get full text

Combination of baseline FDG PET/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma by Toledano, Mathieu Nessim, Desbordes, P., Banjar, A., Gardin, I., Vera, P., Ruminy, P., Jardin, F., Tilly, H., Becker, S.

“…Purpose This study evaluated the predictive significance of total metabolic tumour volume (TMTV) measured on baseline FDG PET/CT and its value in addition to…”
Get full text

High rate of TNFRSF14 gene alterations related to 1p36 region in de novo follicular lymphoma and impact on prognosis by Launay, E, Pangault, C, Bertrand, P, Jardin, F, Lamy, T, Tilly, H, Tarte, K, Bastard, C, Fest, T

“…Follicular lymphoma (FL) is characterized by the balanced chromosomal translocation t(14;18)(q32;q21) in about 80-90% of the cases. This primary event is not…”
Get full text

EZH2 alterations in follicular lymphoma: biological and clinical correlations by Huet, S, Xerri, L, Tesson, B, Mareschal, S, Taix, S, Mescam-Mancini, L, Sohier, E, Carrère, M, Lazarovici, J, Casasnovas, O, Tonon, L, Boyault, S, Hayette, S, Haioun, C, Fabiani, B, Viari, A, Jardin, F, Salles, G

“…The histone methyltransferase EZH2 has an essential role in the development of follicular lymphoma (FL). Recurrent gain-of-function mutations in EZH2 have been…”
Get full text

Predictors of Quit Attempts and Abstinence Among Smokers not Currently Interested in Quitting by Jardin, Bianca F., Carpenter, Matthew J.

“…Rates of quitting smoking remain stagnant, and thus it is becoming increasingly important to identify determinants of successful quitting behavior. The primary…”
Get full text

Effect of single-unit transfusion in patients treated for haematological disease including acute leukemia: A multicenter randomized controlled clinical trial by Chantepie, S.P., Mear, J.B., Briant, A.R., Vilque, J.P., Gac, A.C., Cheze, S., Girault, S., Turlure, P., Marolleau, J.P., Lebon, D., Charbonnier, A., Jardin, F., Lenain, P., Peyro-Saint-Paul, L., Abonnet, V., Dutheil, J.J., Chene, Y., Bazin, A., Reman, O., Parienti, J.J.

“…Retrospective studies in hematological unit have suggested that single red blood cell (1-RBC) unit transfusion policy may reduce the number of RBC used without…”
Get full text

Race and Medication Adherence Moderate Cessation Outcomes in Criminal Justice Smokers by Cropsey, Karen L., PsyD, Clark, C. Brendan, PhD, Zhang, Xiao, PhD, Hendricks, Peter S., PhD, Jardin, Bianca F., PhD, Lahti, Adrienne C., MD

“…Introduction Smokers in the criminal justice system represent some of the most disadvantaged smokers in the U.S., as they have high rates of smoking (70%–80%)…”
Get full text

Somatic mutations of cell-free circulating DNA detected by next-generation sequencing reflect the genetic changes in both germinal center B-cell-like and activated B-cell-like diffuse large B-cell lymphomas at the time of diagnosis by Bohers, Elodie, Viailly, Pierre Julien, Dubois, Sydney, Bertrand, Philippe, Maingonnat, Catherine, Mareschal, Sylvain, Ruminy, Philippe, Picquenot, Jean-Michel, Bastard, Christian, Desmots, Fabienne, Fest, Thierry, Leroy, Karen, Tilly, Hervé, Jardin, Fabrice

Get full text

Prognostic Value of Lymphopenia and Total Metabolic Tumor Volume in Diffuse Large Cell Lymphoma of B Phenotype in the RT3 and REMARC trials—A LYSA retrospective analysis by Willaume, A., Chartier, L., Ricci, R., Blanc‐Durand, P., Amorim, S., Haioun, C., Thieblemont, C., Legouill, S., Casasnovas, O., Morschhauser, F., Jardin, F., Pascal, L.

Get full text

COMBINING BASELINE TOTAL METABOLIC TUMOR VOLUME AND BETA‐2‐MICROGLOBULIN LEVELS PREDICTS OUTCOMES IN HIGH BURDEN FOLLICULAR LYMPHOMA by Zduniak, A., Lévêque, E., Draye‐Carbonnier, S., Becker, S., Tonnelet, D., Dubois, S., Vera, P., Tilly, H., Jardin, F., Decazes, P., Camus, V.

Get full text

Bulimic symptoms in undergraduate men and women: Contributions of mindfulness and thought suppression by Lavender, Jason M., Jardin, Bianca F., Anderson, Drew A.

“…Experiential avoidance, the refusal to accept contact with unpleasant private experiences, is believed to play a role in the onset and maintenance of eating…”
Get full text

Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas by BERTRAND, P, BASTARD, C, MAINGONNAT, C, JARDIN, F, MAISONNEUVE, C, COUREL, M.-N, RUMINY, P, PICQUENOT, J.-M, TILLY, H

“…Chromosomal translocations joining the immunoglobulin (IG) and MYC genes have been extensively reported in Burkitt's and non-Burkitt's lymphomas but data…”
Get full text

Evaluating the Effect of Access to Free Medication to Quit Smoking: A Clinical Trial Testing the Role of Motivation by Jardin, Bianca F., Cropsey, Karen L., Wahlquist, Amy E., Gray, Kevin M., Silvestri, Gerard A., Cummings, K. Michael, Carpenter, Matthew J.

“…Although the majority of smokers are ambivalent about quitting, few treatments specifically target smokers lacking motivation to quit in the near future. Most…”
Get full text

CIRCULATING TUMOR DNA (CTDNA) STATUS AND CLINICAL OUTCOMES IN PATIENTS (PTS) WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) IN THE POLARIX STUDY by Herrera, A. F., Tracy, S., Sehn, L. H., Jardin, F., Lenz, G., Trněný, M., Salles, G., Flowers, C. R., Tilly, H., Sharman, J. P., Friedberg, J. W., Balasubramanian, S., Raghavan, V., Hirata, J., Lee, C., Jiang, Y., Morschhauser, F.

Get full text

Real-world data for marginal zone lymphoma patients in the French REALYSA cohort: The REALMA study by Bommier, C, Donzel, M, Rossi, C, Fornecker, L M, Bijou, F, Chauchet, A, Lebras, L, Ysabaert, L, Haioun, C, Bouabdallah, K, Gastinne, T, Morineau, N, Amorim, S, Jardin, F, Abraham, J, Lamy de la Chapelle, T, Gressin, R, Fouillet, L, Fruchart, C, Olivier, G, Morschhauser, F, Cherblanc, F, Belot, A, Le Guyader, S, Monnereau, A, Ghesquieres, H, Thieblemont, C

“…Marginal Zone Lymphoma (MZL) comprises three subtypes: extranodal MZL (EMZL), splenic MZL (SMZL) and nodal MZL (NMZL). Since clinical trials have limited…”
Get full text

BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial by Petrella, T., Copie-Bergman, C., Brière, J., Delarue, R., Jardin, F., Ruminy, P., Thieblemont, C., Figeac, M., Canioni, D., Feugier, P., Fabiani, B., Leroy, K., Parrens, M., André, M., Haioun, C., Salles, G.A., Gaulard, P., Tilly, H., Jais, J.P., Molina, T.J.

“…Our aim was to evaluate whether the cell of origin (COO) as defined by the Hans algorithm and MYC/BCL2 coexpression, which are the two main biological risk…”
Get full text

AXICABTAGENE CILOLEUCEL AS SECOND‐LINE THERAPY FOR LARGE B‐CELL LYMPHOMA IN TRANSPLANT‐INELIGIBLE PATIENTS: FINAL ANALYSIS OF ALYCANTE, A PHASE 2 LYSA STUDY by Houot, R., Bachy, E., Cartron, G., Gros, F., Morschhauser, F., Oberic, L., Gastinne, T., Feugier, P., Dulery, R., Thieblemont, C., Joris, M., Jardin, F., Choquet, S., Casasnovas, O., Brisou, G., Cheminant, M., Bay, J., Gutierrez, F. Llamas, Menard, C., Tarte, K., Delfau, M., Itti, E., Bailly, C., Al Tabaa, Y., Laurent, C., Lemonnier, F.

Get full text

REALMA: Subset of patients with Marginal Zone Lymphomas from the French nationwide REALYSA real‐world prospective cohort by Bommier, C., Donzel, M., Rossi, C., Fornecker, L., Bijou, F., Chauchet, A., Lebras, L., Ysebaert, L., Haioun, C., Bouabdallah, K., Morineau, N., Gastinne, T., Amorim, S., Jardin, F., Abraham, J., Lamy de la Chapelle, T., Gressin, R., Fouillet, L., Fruchart, C., Morschhauser, F., Olivier, G., Cherblanc, F., Belot, A., Le Guyader, S., Monnereau, A., Ghesquières, H., Thieblemont, C.

Get full text

VERY LONG‐TERM FOLLOW‐UP OF RITUXIMAB MAINTENANCE IN YOUNG PATIENTS WITH MANTLE CELL LYMPHOMA INCLUDED IN THE LYMA TRIAL, A LYSA STUDY by Sarkozy, C., Thieblemont, C., Oberic, L., Moreau, A., Bouabdallah, K., Damaj, G., Gastine, T., Ribrag, V., Casasnovas, O., Haioun, C., Houot, R., Jardin, F., Neste, E., Cheminant, M., Morschhauser, F., Callana, M., Ghesquieres, H., Gressin, R., Hermine, O., Le Gouill, S.

Get full text

IMMUNE CONTEXTURE ANALYSIS IN POLARIX SUGGESTS RESPONSE TO POLA‐R‐CHP TREATMENT REDUCES TUMOR MICROENVIRONMENT DEPENDENCY by Morschhauser, F., Hatzi, K., Lenz, G., Herrera, A. F., Flowers, C. R., Trněný, M., Burke, J. M., Hou, J., Staber, P. B., Hawkes, E. A., Izutsu, K., Le Gouill, S., Belada, D., Tucci, A., Yan, M., Harris, W., Hirata, J., Lee, C., Jiang, Y., Jardin, F.

Get full text